NDARECTALSUPPOSITORY
Approved
Apr 1960
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
2/8 — Basic
PHENERGAN (promethazine hydrochloride) by Teva is clinical pharmacology promethazine is a phenothiazine derivative which differs structurally from the antipsychotic phenothiazines by the presence of a branched side chain and no ring substitution. First approved in 1960.
Drug data last refreshed 8h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
PHENERGAN (promethazine HCl) is a first-generation phenothiazine derivative that acts as an H1 receptor antagonist with sedative and antiemetic properties. Approved in 1960, it is indicated for allergic conditions, nausea/vomiting, and sedation across multiple routes of administration. The rectal suppository formulation provides clinical effects within 20 minutes and duration of 4–12 hours via hepatic metabolism.
LOE Approaching
As LOE approaches, brand team focus will shift from growth initiatives to lifecycle extension strategies and managed decline; team size likely stable or contracting.
Mechanism of Action
CLINICAL PHARMACOLOGY Promethazine is a phenothiazine derivative which differs structurally from the antipsychotic phenothiazines by the presence of a branched side chain and no ring substitution. It is thought that this configuration is responsible for its relative lack (1/10 that of…
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
PHENERGAN offers limited career growth opportunity due to LOE-approaching status and zero linked job openings; roles available are primarily defensive and operational rather than strategic. This product is best suited for professionals seeking stable, maintenance-focused experience in a mature therapeutic category, not for those targeting innovation-driven career progression.
Worked on PHENERGAN at Teva? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.